Optimization of a widefield structured illumination microscope for non-destructive assessment and quantification of nuclear features in tumor margins of a primary mouse model of sarcoma.
Date
2013-01
Editors
Journal Title
Journal ISSN
Volume Title
Repository Usage Stats
views
downloads
Citation Stats
Attention Stats
Abstract
Cancer is associated with specific cellular morphological changes, such as increased nuclear size and crowding from rapidly proliferating cells. In situ tissue imaging using fluorescent stains may be useful for intraoperative detection of residual cancer in surgical tumor margins. We developed a widefield fluorescence structured illumination microscope (SIM) system with a single-shot FOV of 2.1 × 1.6 mm (3.4 mm(2)) and sub-cellular resolution (4.4 µm). The objectives of this work were to measure the relationship between illumination pattern frequency and optical sectioning strength and signal-to-noise ratio in turbid (i.e. thick) samples for selection of the optimum frequency, and to determine feasibility for detecting residual cancer on tumor resection margins, using a genetically engineered primary mouse model of sarcoma. The SIM system was tested in tissue mimicking solid phantoms with various scattering levels to determine impact of both turbidity and illumination frequency on two SIM metrics, optical section thickness and modulation depth. To demonstrate preclinical feasibility, ex vivo 50 µm frozen sections and fresh intact thick tissue samples excised from a primary mouse model of sarcoma were stained with acridine orange, which stains cell nuclei, skeletal muscle, and collagenous stroma. The cell nuclei were segmented using a high-pass filter algorithm, which allowed quantification of nuclear density. The results showed that the optimal illumination frequency was 31.7 µm(-1) used in conjunction with a 4 × 0.1 NA objective (v=0.165). This yielded an optical section thickness of 128 µm and an 8.9 × contrast enhancement over uniform illumination. We successfully demonstrated the ability to resolve cell nuclei in situ achieved via SIM, which allowed segmentation of nuclei from heterogeneous tissues in the presence of considerable background fluorescence. Specifically, we demonstrate that optical sectioning of fresh intact thick tissues performed equivalently in regards to nuclear density quantification, to physical frozen sectioning and standard microscopy.
Type
Department
Description
Provenance
Subjects
Citation
Permalink
Published Version (Please cite this version)
Publication Info
Fu, Henry L, Jenna L Mueller, Melodi P Javid, Jeffrey K Mito, David G Kirsch, Nimmi Ramanujam and J Quincy Brown (2013). Optimization of a widefield structured illumination microscope for non-destructive assessment and quantification of nuclear features in tumor margins of a primary mouse model of sarcoma. PloS one, 8(7). p. e68868. 10.1371/journal.pone.0068868 Retrieved from https://hdl.handle.net/10161/26067.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Scholars@Duke
Melodi Javid Whitley
Melodi Javid Whitley, MD, PhD
Assistant Professor of Dermatology
Assistant Program Director for Trainee Research
Director of Transplant Dermatology
I am a physician scientist focused on the dermatologic care of solid organ transplant recipients. Clinically, I manage the the complex dermatologic side effects of immunosuppression with a focus on high-risk skin cancer. My research focuses on understanding the drivers of cutaneous malignancy in this population using translational approaches.
Nimmi Ramanujam
Nirmala (“Nimmi”) Ramanujam is the Robert W. Carr Professor of Biomedical Engineering and Professor of Cancer Pharmacology, Cancer Biology, and Global Health at Duke University. In 2013, she founded the Center for Global Women’s Health Technologies (GWHT) to advance technology-driven solutions for women’s health. Her work leads translational cervical and breast cancer research that brings together academic institutions, hospitals, industry partners, and non-governmental organizations in the United States and around the world. Across both disease areas, her research emphasizes the translation of engineering innovation into real-world clinical impact, with a focus on equitable and sustainable cancer care.
In cervical cancer, Ramanujam has developed low-cost, point-of-care screening systems that integrate portable and self-imaging devices, contrast-enhanced imaging, and AI-driven diagnostics. These approaches enable task-shifting of early cancer surveillance from specialists to midwives and community health workers. Her collaborative efforts have led to the implementation of a successful “see-and-treat” program in the Andean region of Peru, with ongoing work to establish similar models in Kenya.
In breast cancer, her research aims to reduce overtreatment and prevent recurrence through complementary therapeutic and imaging strategies. These include localized immunomodulatory therapies that activate anti-tumor immunity with minimal systemic toxicity, as well as real-time metabolic imaging technologies that provide early indicators of relapse risk and treatment response.
Alongside her research, Ramanujam is deeply engaged in advancing education, entrepreneurship, and translation in women’s health technologies. In 2019, she founded Calla Health to commercialize innovations from her laboratory, reaching more than 8,000 women across 11 countries. She also co-developed The (In)visible Organ, a femtech documentary selected for the Women at the Center Film Festival, and leads Bass Connections initiatives that provide project-based learning opportunities in STEM and health care technologies.
Ramanujam has received numerous honors for leadership and innovation, including the Department of Defense Breast Cancer Innovator Award, the IEEE Biomedical Engineering Technical Field Award, and the AnitaB.org Social Impact Award. She is a Fellow of the National Academy of Engineering and the National Academy of Inventors, a Fulbright Scholar, and the author of Biomedical Engineering for Global Health, which connects engineering principles to real-world global health challenges.
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.
